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OBJECTIVES: Noonan and Noonan-related syndromes are common autosomal dominant disorders with neuro-
cardio-facial-cutaneous and developmental involvement. The objective of this article is to describe the most
relevant tegumentary findings in a cohort of 41 patients with Noonan or Noonan-related syndromes and to
detail certain aspects of the molecular mechanisms underlying ectodermal involvement.
METHODS: A standard questionnaire was administered. A focused physical examination and a systematic
review of clinical records was performed on all patients to verify the presence of tegumentary alterations. The
molecular analysis of this cohort included sequencing of the following genes in all patients: PTPN1, SOS1, RAF1,
KRAS, SHOC2 and BRAF.
RESULTS: The most frequent tegumentary alterations were xeroderma (46%), photosensitivity (29%), excessive
hair loss (24%), recurrent oral ulcers (22%), curly hair (20%), nevi (17%), markedly increased palmar and plantar
creases (12%), follicular hyperkeratosis (12%), palmoplantar hyperkeratosis (10%), cafe´-au-lait spots (10%) and
sparse eyebrows (7%). Patients with mutations in PTPN11 had lower frequencies of palmar and plantar creases
and palmar/plantar hyperkeratosis compared with the other patients.
CONCLUSIONS:We observed that patients with mutations in genes directly involved in cell proliferation kinase
cascades (SOS1, BRAF, KRAS and RAF1) had a higher frequency of hyperkeratotic lesions compared with
patients with mutations in genes that have a more complex interaction with and modulation of cell
proliferation kinase cascades (PTPN11).
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& INTRODUCTION
Noonan syndrome (NS; Online Mendelian Inheritance in
Man [OMIM] 163950) and Noonan-related syndromes
(NRS), such as cardiofaciocutaneous (CFC) syndrome
(OMIM 115150), NS with multiple lentigines (NSML];
OMIM 151100), Costello syndrome (CS; OMIM 218040),
neurofibromatosis type I (NFI; OMIM 162200), Legius
syndrome (LS; OMIM 611431) and NS with loose anagen
hair (NSLAH; OMIM 607721) are common autosomal
dominant disorders with neuro-cardio-facial-cutaneous
and developmental involvement. These syndromes share
common traits, such as craniofacial dysmorphisms, short
stature, cardiac malformations, variable cognitive impair-
ment, an increased risk of cancer development and a certain
extent of tegumentary involvement (1).
These disorders are caused by germline mutations in
genes that participate in the rat sarcoma/mitogen-activated
protein kinase (RAS/MAPK) pathway, which transduces
extracellular growth factor signals into the intracellular
environment and plays a role in cell cycle regulation,
differentiation, growth and death and affects the inflamma-
tory response (2,3). Although the role of the RAS/MAPK
pathway in skin development and functioning is not
completely understood, several skin manifestations in
individuals with NS and NRS have been described, such
as pigmented lesions (cafe´-au-lait [CAL] spots, lentigines
and melanocytic lesions), proliferative ectodermal lesions
(e.g., ichthyosiform manifestations, follicular hyperkerato-
sis, and short, curly and thin hair) and hyperplasia
(redundant skin and papillomatous growths) (1,4). Several
of these skin manifestations are associated with a specific
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syndromic phenotype, such as lentigines in NSML patients,
thin, sparse hair in NSLAH patients and hyperkeratotic skin
in CFC syndrome and in NS patients harboring SOS1 gene
mutations (1). The exact underlying molecular mechanism
determining the diverse physiopathological spectrum of
lesions, the association of specific tegumentary lesions with
specific syndromes and the increased prevalence of tegu-
mentary involvement in groups with mutations in specific
genes is still unknown (1,5-7).
The exact delineation of the tegumentary findings in each
group of patients harboring mutations in different genes, a
comprehensive genotype-phenotype correlation in NS and
NRS patients and a model of the molecular mechanisms of
the diseases all remain to be determined.
The objective of this article is to describe the most relevant
tegumentary findings in a cohort of 41 patients with NS or
NRS who harbor a confirmed germline mutation in genes of
the RAS/MAPK pathway and to unveil certain aspects of
the molecular mechanisms underlying ectodermal involve-
ment in NS and NRS patients by comparing the clinical
features of patient groups classified by their gene mutations.
& MATERIALS AND METHODS
A prospective study that included 41 patients affected by
NS or NRS was performed at the Outpatient Clinic of the
Genetics Unit of Instituto da Crianc¸a do Hospital das
Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o
Paulo. The majority of these patients were referred to our
unit by pediatric endocrinology and cardiology services.
Consensus clinical criteria were used to classify the patients
as being affected by NS, NSML or CFC syndrome (8-11).
Only one patient, who had tested negative for the
previously described gene alterations in other known NS-
related genes (PTPN11, SOS1, RAF1 and KRAS), was
diagnosed with NSLAH by the presence of slow growth,
fine hair and a SHOC2 gene mutation (p.S2G). Another
patient, who presented with the mutation p.T468M in the
PTPN11 gene, which is usually associated with NSML, was
classified as an NS patient because he lacked lentigines by
the age of 21 years.
The molecular analysis of this cohort included the
sequencing of the following genes in all patients: PTPN11,
SOS1, RAF1, KRAS and SHOC2. Additionally, the BRAF
gene was analyzed in patients fulfilling CFC syndrome
diagnostic criteria. The p.T470P (BRAF gene) gene alteration
was novel; in silico prediction (PolyPhen, SIFT and
Mutation Taster) suggested that the mutation damaged
the protein structure and affected protein function, indicat-
ing the alteration’s pathogenicity. The mutation was a de
novo event in the family.
A standard questionnaire was administered, and a
focused physical examination based on a systematic review
of clinical records was performed on all patients to verify
the presence of the following complaints: xeroderma (the
presence of dry skin, indicated by either scaling or cracking
of the skin upon clinical examination), photosensitivity (a
subjective impression of greater skin redness following sun
exposure), hair loss (a subjective sensation of thinning of the
hair), lentigines (the presence of .100 lentiginous lesions),
CAL spots (uniformly light brown, sharply defined and
usually oval-shaped skin patches), thin hair, curly hair,
sparse eyebrows, a clinical history of recurrent oral ulcers,
nevi (at least 100), hyperpigmentation of the skin (increased
pigmentation of the skin compared with other family
members), cutis marmorata (a reticulated cutaneous vascu-
lar pattern with altered color (red or blue), follicular
hyperkeratosis, palmo-plantar hyperkeratosis (the presence
of areas of thickening of the skin in the palmar and plantar
regions), markedly increased palmar and plantar creases,
keloid scars (excessive growth of scar tissue), nasal
papilloma (cauliflower-like epithelial lesions) and the early
onset of gray hair. The presence or absence of subjective
clinical signs was based on the clinical impression of the
genetic unit team, which is experienced when evaluating
patients with NS and NRS. Therefore, the clinical protocol
and physical examination were applied using the same
clinical criteria for all patients.
Statistical analyses comparing the between-group differ-
ences, which were stratified by age, gender and gene
mutation, were performed using Fisher’s exact test with a
significance limit of 0.05. The Student’s t-test was used to
compare the frequency distribution of tegumentary findings
between a group of patients with mutations in PTPN11 and
a group that comprised the remaining individuals. The
samples did not show any deviation related to gender or
age, indicating that sample bias was unlikely.
Ethics
The local ethics committee (Comissa˜o de E´tica para
Ana´lise de Projetos de Pesquisa [CAPPesq] do Hospital
das Clı´nicas da Faculdade de Medicina da Universidade de
Sa˜o Paulo - 0843/08 and 0325/10) approved this study, and
written informed consent was obtained from all partici-
pants.
& RESULTS
Patients ranged in age from five to 58 years, with a mean
age of 20 years and a median age of 17 years. Gender was
almost equally distributed (21 females and 20 males). The
cohort was composed of 36 NS patients, two CFC syndrome
patients, two NSML patients and one NSLAH patient. The
molecular analysis identified 30 patients harboring muta-
tions in PTPN11, five in SOS1, two in BRAF, two in RAF1,
one in SHOC2 and one in KRAS. Most individuals (34
patients, 83%) were sporadic cases caused by a de novo
mutation, whereas familiar aggregation was found in seven
patients (three individuals in one family and two indivi-
duals in each of two families).
The following tegumentary alterations were observed, in
order of prevalence: xeroderma (46%), photosensitivity
(29%), excessive hair loss (24%), recurrent oral ulcers
(22%), curly hair (29%), nevi (20%), follicular hyperkeratosis
(17%), markedly increased palmar and plantar creases
(15%), CAL spots (15%), sparse eyebrows (12%), palmo-
plantar hyperkeratosis (10%), lentigines (5%), keloid scars
(5%), hyperpigmentation of the skin (5%), nasal papilloma
(2%), the early onset of gray hair (2%), cutis marmorata (2%)
and thin hair (2%). The great majority of individuals (93%)
presented with at least one tegumentary involvement (mean
of three, median of two, maximum of nine), whereas three
individuals did not present with any tegumentary involve-
ment. The most relevant clinical characteristics of these
patients are summarized in Table 1 and shown in Figure 1.
The mean number of positive tegumentary findings was
highest in the group of patients with CFC syndrome (n = 6
findings/individual), followed by NSML (n = 5), NSLAH
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(n = 4) and NS (n = 2). When we stratified the patients by the
affected gene, the ranking of the mean number of positive
tegumentary findings per individual in each group was as
follows: KRAS (n = 9 findings/individual), BRAF (n = 6),
SHOC2 (n = 4), PTPN11 (n = 3), SOS1 (n = 2) and RAF1
(n = 1).
The distribution of the number of tegumentary findings in
patients harboring PTPN11 mutations (mean = 1.9, standard
deviation [SD] = 1.42) compared with patients with muta-
tions in other genes (mean = 3.6, SD = 2.6) showed a
significant difference (p= 0.0352).
CAL spots were more common in males (p= 0.0471).
Follicular hyperkeratosis was statistically more prevalent in
postpubertal (.16 years of age) patients (p= 0.0269). No
patients harboring a PTPN11 mutation developed a nevus
prior to the age of 11 years in contrast to patients harboring
other gene mutations (p= 0.0476).
Patients with PTPN11 mutations had a lower frequency of
follicular hyperkeratosis (3.5% vs. 40%, p= 0.011) and
markedly increased palmar and plantar creases (3.5% vs.
40%, p= 0.011) and palmar/plantar hyperkeratosis (3.5% vs.
30%, p= 0.0449) compared with other patients. Comparing
the PTPN11 patients with the SOS1 patients, the PTPN11
patients had a lower frequency of follicular hyperkeratosis
(3.5% vs. 50%, p= 0.0326) and markedly increased palmar
and plantar creases (3.5% vs. 75%, p= 0.0029).
& DISCUSSION
In the current study, we described the most relevant
tegumentary findings in a cohort of 41 patients with a
molecularly proven diagnosis of NS or NRS. We found that
these tegumentary findings are common in these syn-
dromes, particularly in patients with BRAF, KRAS and
SHOC2 mutations. Note that this phenomenon was demon-
strated in a sample composed of mostly young individuals.
This report is the first comprehensive study in the literature
to address tegumentary involvement in NS patients with
germline mutations in several genes of the RAS/MAPK
pathway. Several of the manifestations reported in this
article have not been previously described in the literature,
including the frequency of tegumentary involvement in this
syndromic group as a whole.
The association of CAL spots with male gender is not
exclusive to our group of patients because CAL spots are
more commonly observed in normal males than in normal
females (12). We also observed that follicular hyperkeratosis
and nevi are associated with postpubertal age, which we
speculate is because of an accumulation of sun exposure or
hormonal influence.
The RAS/MAPK signaling pathway receives extracellular
stimuli from cell surface receptors and acts as a molecular
switch in the processes of cell proliferation, differentiation,
survival and death (13). Several components of this pathway
are related to the promotion of epidermal proliferation and
may interfere in the epidermal cell state (4,14). Signal
transmission is initiated by the extracellular stimulators
(growth factors, hormones and cytokines) that create
intracellular docking sites for adaptor molecules activating
cell surface receptors. This interaction promotes the activa-
tion of RAS GTPases, including the products of KRAS,
NRAS and HRAS (monomeric GTPases that use GDP/GTP-
regulated molecular switching to control intracellular signal
Table 1 - Genetic and clinical profiles of the 41 patients diagnosed with Noonan syndrome and Noonan-related
syndromes. The syndrome column shows the clinical diagnosis of the patients; the gene column contains each gene; the
mutation column contains the pathogenic alteration in the product of the genes; and the clinical characteristics column
shows the most relevant clinical features of each patient, including age and gender, and tegumentary involvement is in
brackets. Note that patients with no tegumentary involvement are indicated in bold.
Syndrome Gene Mutation Clinical characteristics
NS PTPN11 p.G60A 29 yo Male (OU; N; CAL; GH)
p.Y62D 24 yo Male (Xe; N; CAL)
p.Y63C 9 yo Male (P; PH; FH) | 9 yo Female (Xe; OU) I 11 yo Male (Xe)
p.Q79R 23 yo Female (CM) | 19 yo Male (Xe; P; OU)
p.D106A 10 yo Female (SE)
p.I282V 12 yo Male (Xe)
p.F285S 33 yo Female (Xe; P; HL; Cr; FH; CH; SE)
p.N308D 13 yo Female | 17 yo Female (CH; FH) | 22 yo Male (Xe; P; OU; CH) | 56 yo Male (HL) | 11 yo Female
(Xe; P; OU) | 12 yo Male (N) | 21 yo Female (Xe; HL) | 5 yo Female (CH; SE) | 20 yo Male (Xe)
p.N308S 29 yo Male | 56 yo Female | 16 yo Female (HL; Ke) | 32 yo Female (CH; P; N) | 15 yo Female (HL; N;
Ke) | 11 yo Male (Xe; CH)
p.T468M 21 yo Male (N; CAL; Cr)
p.M504V 12 yo Male (P; OU)
p.Q510P 8 yo Male (CH; CAL)
RAF1 p.P235S 12 yo Female (PH)
p.S257K 8 yo Male (N)
SOS1 p.M269T 27 yo Male (Xe; P; CH; Cr; FH; HS) | 58 yo Female (Xe; HL) | 7 yo Male (Cr)
p.R552G 28 yo Female (P; Cr; FH; CH)
p.R552S 13 yo Male (CAL)
KRAS p.K5E 24 yo Female (Xe; HL; OU; CH; Cr; FH; HS; NP; Ly)
CFC BRAF p.N581D 17 yo Female (Xe; P; CH; FH; PH; SE)
p.T470P 9 yo Female (Xe; HL; CH; N; PH; SE)
NSML PTPN11 p.Y279C 31 yo Female (Xe; P; CAL; Le) | 18 yo Female (Xe; P; HL; OU; Le)
NSLAH SHOC2 p.S2G 40yo Male (Xe; HL; OU; TH)
Xe: xeroderma, P: photosensitivity, HL: excessive hair loss, OU: recurrent oral ulcers, CH: curly hair, N: nevus, Cr: markedly increased palmar and plantar
creases, FH: follicular hyperkeratosis, PH: palmo-plantar hyperkeratosis, CAL: cafe´-au-lait spots, SE: sparse eyebrows, Le: lentigines, Ke: keloid scars, HS:
hyperpigmentation of the skin, NP: nasal papilloma, GH: the early onset of gray hair, CM: cutis marmorata, TH: thin hair.
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flow), and, therefore, the interaction and activation of the
RAF protein kinase components, including the products of
RAF1 and BRAF, members of a small family of serine-
threonine kinases that function as RAS effectors. Activating
the RAF cascade results in the phosphorylation and activa-
tion of the final MAPK components (the substrates of the
pathway) and, consequently, cellular responses (1,4,13,14).
The PTPN11 gene encodes SHP2, a cytoplasmic protein
tyrosine phosphatase that positively modulates RAS signal-
ing through its interaction with the GRB2/SOS1 complex.
SHP2 also exhibits other intricate, contradictory and rela-
tively unknown interactions. SOS1 encodes a multidomain
product that catalyzes the release of GDP from RAS through
a close interaction with GRB2. This event facilitates the
conversion of the inactive form of RAS into its active GTP-
bound state. The SHOC2 gene encodes a protein that
positively modulates the RAS-MAPK signal flow (1,4,14,15).
Interestingly, PTPN11 is the only studied gene that also
functions as a downregulator (unlike SOS1, KRAS, RAF1 and
BRAF) (National Cancer Institute, Pathway Interaction
Database, USA). For example, PTPN11 specifically inhibits
the GRB2/SOS1 complex in the neuromuscular junction (16).
We observed that patients with mutations in genes
directly involved in the kinase cascades for cell proliferation
(SOS1, BRAF, KRAS and RAF1) have a higher frequency of
proliferative skin lesions (hyperkeratosis and marked
palmar and plantar creases) compared with patients with
mutations in a gene that has a more complex interaction
with and modulation of this transduction pathway
(PTPN11). Previous studies have also supported this
observation. Hyperkeratosis has been described in patients
harboring mutations in those genes. Additionally, patients
with mutations in MEK1 and MEK2, the final effectors of the
MAPK cascade, develop remarkable tegumentary involve-
ment that usually includes hyperkeratosis (7). Activation of
the RAS/MAPK pathway by a contradictory effect of
dabrafenib, a BRAF inhibitor used to treat melanoma,
induces the proliferation of keratinocytes and predisposes
patients to hyperkeratosis (17).
Limitations of this study include the descriptive nature of
the data and the relatively small sample size for statistical
analysis, although a sample size of 41 is considerable for
rare genetic disorders. Additionally, several tegumentary
findings described here (i.e., xeroderma and photosensitiv-
ity) are either common in the normal population or are
diagnosed solely based on patient complaints or the clinical
impression of the examiner; therefore, the prevalence of
these conditions in our patients may have been inflated.
Despite our work to improve the delineation of tegumentary
genotype-phenotype correlations in this study, we encou-
rage further investigation in this field.
A thorough description of dermatological findings has been
developed for Costello syndrome, an NRS caused by germline
mutations in HRAS (5). Costello syndrome patients have a
statistically higher frequency of cutaneous papillomas and
palmar hyperkeratosis but a lower frequency of sparse
eyebrows compared with patients with CFC syndrome (i.e.,
harboring mutations in BRAF). Although our study did not
include patients with Costello syndrome or any patients with
HRAS mutations, one patient with a KRAS mutation
presented with nasal papilloma and other characteristics that
overlap with the characteristics observed in Costello syn-
drome, such as distal hyperextensibility, marked palmar
creases and facial dysmorphisms (18). As this patient
Figure 1 - Mosaic showing several tegumentary findings of the patients reported in this article. A and B) A patient with Noonan
syndrome with loose anagen hair and SHOC2 mutation (p.S2G) who presented with thin hair and premature baldness; C) a patient with
Noonan syndrome and PTPN11 (p.G60A) mutation with premature graying of the hair; D) a patient with CFC syndrome (BRAF
p.N581D), sparse eyebrows and follicular hyperkeratosis; E) a patient with Noonan syndrome (PTPN11 p.T468 M) who presented with
cafe´-au-lait spots and prominent pectus excavatum; F and G) a patient with Noonan syndrome (KRAS p.K5E), nasal papillomas and
marked plantar creases; 1H: a patient with CFC syndrome (BRAF p.T470P) and plantar hyperkeratosis.
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presented with several tegumentary findings and was the
only one harboring a KRAS mutation, we may have over-
estimated the prevalence of skin abnormalities in patients
with this gene mutation.
Cutaneous manifestations in patients with BRAF muta-
tions (i.e., mainly patients with CFC syndrome) have also
been reported, with a high frequency of melanocytic nevi,
hyperkeratosis of the palms and soles (typically developed
in pressure areas) and follicular hyperkeratosis (6).
Tegumentary involvement in NS and NRS patients was
common, even in a sample composed of mostly young
individuals. Therefore, an active search for cutaneous
involvement in NS and NRS patients and the addition of
dermatologists to the multidisciplinary team required to
assist these patients is necessary for optimal follow-up
treatment. Clinicians must keep in mind that several of
these skin lesions could have a late onset and thus hinder a
straight genotype-phenotype correlation.
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